research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-20 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
== Mycelium-based textiles == Mycelium, the vegetative part of fungi, has emerged as a versatile and sustainable raw material for biotextiles. Mycelium typically grows underground or within its substrate such as soil, wood, decaying organic matter or waste residues. In mycelium-based biocomposites, the fungus consumes the carbohydrates to produce hyphae, a network of branching, thread-like structures. Through controlled growth processes, mycelium can be cultivated into a dense network of interwoven fibers, forming a durable biodegradable matrix suitable for textile applications. This cultivation depends on the temperature, moisture and pH of the media.
A flexible intermediate bulk container, FIBC, big bag, bulk bag, or super sack is a standardized container in large dimensions for storing and transporting granular products. It is often made of a woven synthetic material.
The R1 plasmid is a plasmid that was first isolated from Salmonella paratyphi bacteria in 1963. It is a short plasmid, composed of 97,566 nucleotides and 120 genes, that belongs to the IncFII plasmid group. There are about one to two copies of the R1 plasmid per chromosome. The R1 plasmid imparts multi-drug antibiotic resistance to its host bacteria. The "R" in "R1" stands for "resistance", and the R1 plasmid contains resistance factors, or R factors, giving it the power to resist certain antibiotics. It's known as a "low copy" plasmid, meaning that it exists in relatively few copies in any given bacteria. This characteristic allows the R1 plasmid to have an efficient plasmid stabilization system, that aids in stabilizing medium copy number plasmids. R1 must rely on a "Type II" segregation system. This plasmid system ensures that at least one copy is contained in each daughter cell after cell division.
Sources: en.wikipedia.org
The mechanism of the Hofmeister series is not entirely clear, but seems to result mainly from effects on the solvent at higher salt concentrations (> 100 mM). Early members of the series increase solvent surface tension and decrease the solubility of nonpolar molecules (salt out); in effect, they strengthen the hydrophobic interaction. By contrast, later salts in the series increase the solubility of nonpolar molecules (salt in) and decrease the order in water; in effect, they weaken the hydrophobic effect. However, these salts also interact directly with proteins (which are charged and have strong dipole moments) and may even bind specifically (e.g., phosphate and sulfate binding to ribonuclease A). Ions that have a strong salting in effect such as I− and SCN− are strong denaturants, because they salt in the peptide group, and thus interact much more strongly with the unfolded form of a protein than with its native form. Consequently, they pull the unfolding reaction. Moreover, they may have direct interactions with some standard hydrophobic molecules, e.g., benzene. A quantum chemical investigation suggests an electrostatic origin of the Hofmeister series, which appears to quantify this qualitative series (at least for anions).
Secondly, elements 104 and 105 were given names favored by JINR, despite earlier recognition of LBL as an equal co-discoverer for both of them. Thirdly and most importantly, IUPAC rejected the name seaborgium for element 106, having just approved a rule that an element could not be named after a living person, even though the 1993 report had given the LBL team the sole credit for its discovery. In 1995, IUPAC abandoned the controversial rule and established a committee of national representatives aimed at finding a compromise. They suggested seaborgium for element 106 in exchange for the removal of all the other American proposals, except for the established name lawrencium for element 103. The equally entrenched name nobelium for element 102 was replaced by flerovium after Georgy Flerov, following the recognition by the 1993 report that that element had been first synthesized in Dubna. This was rejected by American scientists and the decision was retracted. The name flerovium was later used for element 114. In 1996, IUPAC held another meeting, reconsidered all names in hand, and accepted another set of recommendations; it was approved and published in 1997. Element 105 was named dubnium (Db), after Dubna in Russia, the location of the JINR; the American suggestions were used for elements 102, 103, 104, and 106. The name dubnium had been used for element 104 in the previous IUPAC recommendation. The American scientists "reluctantly" approved this decision.
Since the RCL is still covalently attached to the protease via the ester bond, the S to R transition pulls protease from the top to the bottom of the serpin and distorts the catalytic triad. The distorted protease can only hydrolyse the acyl enzyme intermediate extremely slowly and so the protease remains covalently attached for days to weeks. Serpins are classed as irreversible inhibitors and as suicide inhibitors since each serpin protein permanently inactivates a single protease, and can only function once.
== Data analysis == Gel permeation chromatography (GPC) has become the most widely used technique for analyzing polymer samples in order to determine their molecular weights and weight distributions. Examples of GPC chromatograms of polystyrene samples with their molecular weights and dispersities are shown on the left.
Sources: en.wikipedia.org
== Similar approaches == Though immunoliposomes serve as a possible advancement, there are other therapies similar to it that trail on the role of targeted drug delivery systems. One example of such therapy is Immune Polymeric nanoparticles, which are similar to liposomes but consist of small particles composed of biodegradable polymers. These nanoparticles similarly encapsulate drugs and can function to enhance specificity towards targeted diseased cells with peptide ligands. Another type is Targeting Antibody Drug Conjugates, which combine monoclonal antibodies with the cytotoxicity of chemotherapy drugs. This specific type is catered towards cancer cells expressing a specific target antigen. They are well-tolerated by the body as they are biodegradable, eliminating many potential toxicity factors, and proving to be a possible new model for therapeutics.
== Health effects == Trifluoroacetic acid is a strong acid. TFA is harmful when inhaled, causes severe skin burns and is toxic for aquatic organisms even at low concentrations. Skin burns are severe, heal poorly and can be necrotic. Vapour fumes have an LC50 of 10.01 mg/L, tested on rats over 4 hours. Inhalation symptoms include mucus irritation, coughing, shortness of breath and possible formation of oedemas in the respiratory tract. Exposure damages the kidneys. TFA is also thought to be responsible for halothane-induced hepatitis. In 2024, the German Federal Institute for Risk Assessment (BfR) formally requested that the European Chemicals Agency (ECHA) reclassify TFA as "presumed" toxic to human reproduction, based on studies showing damage to animal fetuses. In June 2026, ECHA's Risk Assessment Committee (RAC) concluded that TFA fulfils the criteria for toxic to the reproduction class 1B, persistent, mobile and toxic (PMT) as well as very persistent and very mobile (vPvM). In July 2026, the European Food Safety Authority (EFSA) reduced the acceptable daily intake for TFA by 72%, from 0.05 mg/kg body weight/day down to 0.014. It also set the acute reference dose (ARfD) to 0.07 mg/kg body weight. These reductions were based on an assessment of new evidence, including changes in levels of the hormone thyroxine.
=== Neutrophil action === MMP9, along with elastase, appears to be a regulatory factor in neutrophil migration across the basement membrane. MMP9 plays several important functions within neutrophil action, such as degrading extracellular matrix, activation of IL-1β, and cleavage of several chemokines. In a mouse model, MMP9 deficiency resulted in resistance to endotoxin shock, suggesting that MMP9 is important in sepsis.
The addition of mirtazapine to a monoamine oxidase inhibitor, while potentially having typical or idiosyncratic (unique to the individual) reactions not herein described, does not appear to cause serotonin syndrome. This is per the fact that the 5-HT2A receptor is the predominant serotonin receptor thought to be involved in the pathophysiology of serotonin syndrome (with the 5-HT1A receptor seeming to be protective). Mirtazapine is a potent 5-HT2A receptor antagonist, and cyproheptadine, a medication that shares this property, mediates recovery from serotonin syndrome and is an antidote against it. There is a possible interaction that results in a hypertensive crisis when mirtazapine is given to a patient who has already been on steady doses of clonidine. This involves a subtle consideration, when patients have been on chronic therapy with clonidine and suddenly stop the dosing, a rapid hypertensive rebound sometimes (20%) occurs from increased sympathetic outflow. Clonidine's blood pressure lowering effects are due to stimulation of presynaptic α2 autoreceptors in the CNS which suppress sympathetic outflow. Mirtazapine itself blocks these same α2 autoreceptors, so the effect of adding mirtazapine to a patient stabilized on clonidine may precipitate withdrawal symptoms. Mirtazapine has been used as a hallucinogen antidote to block the effects of serotonergic psychedelics like psilocybin and lysergic acid diethylamide (LSD).
According to a Pew Research poll, 49% of Americans opposed the bill, 29% were in favor of the bill, and 21% were unsure. According to an IPSOS-Washington Post poll, 42% of Americans opposed the bill, 23% were in favor of the bill, and 23% were unsure. According to a Fox News poll, 59% of Americans opposed the bill, 29% were in favor. According to KFF, 64% of Americans opposed the bill, 35% were in favor. NPR noted that the bill's passage fulfilled several of Trump's campaign promises, but also violated his promise not to touch Medicaid benefits. CNN described its passage as made possible despite intraparty opposition as an example of "Trump's iron grip on his own party" and an "omnipresent" effort to get Republicans on board despite its unpopularity with the American public. In June 2026, nearly one year after the bill's passage, a Navigator Research poll found that 34% of Americans approved of the law, 53% disapproved, and 13% were unsure.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.